These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19815815)

  • 1. Chylomicronemia elicits atherosclerosis in mice--brief report.
    Weinstein MM; Yin L; Tu Y; Wang X; Wu X; Castellani LW; Walzem RL; Lusis AJ; Fong LG; Beigneux AP; Young SG
    Arterioscler Thromb Vasc Biol; 2010 Jan; 30(1):20-3. PubMed ID: 19815815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons.
    Young SG; Davies BS; Fong LG; Gin P; Weinstein MM; Bensadoun A; Beigneux AP
    Curr Opin Lipidol; 2007 Aug; 18(4):389-96. PubMed ID: 17620854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
    Véniant MM; Pierotti V; Newland D; Cham CM; Sanan DA; Walzem RL; Young SG
    J Clin Invest; 1997 Jul; 100(1):180-8. PubMed ID: 9202070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation?
    Lo CM; Nordskog BK; Nauli AM; Zheng S; Vonlehmden SB; Yang Q; Lee D; Swift LL; Davidson NO; Tso P
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G344-52. PubMed ID: 18006607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution.
    Gin P; Beigneux AP; Davies B; Young MF; Ryan RO; Bensadoun A; Fong LG; Young SG
    Biochim Biophys Acta; 2007 Dec; 1771(12):1464-8. PubMed ID: 17997385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.
    Beigneux AP; Franssen R; Bensadoun A; Gin P; Melford K; Peter J; Walzem RL; Weinstein MM; Davies BS; Kuivenhoven JA; Kastelein JJ; Fong LG; Dallinga-Thie GM; Young SG
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):956-62. PubMed ID: 19304573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
    Véniant MM; Zlot CH; Walzem RL; Pierotti V; Driscoll R; Dichek D; Herz J; Young SG
    J Clin Invest; 1998 Oct; 102(8):1559-68. PubMed ID: 9788969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal metabolic perturbations in the adipose tissue and liver of GPIHBP1-deficient mice.
    Weinstein MM; Goulbourne CN; Davies BS; Tu Y; Barnes RH; Watkins SM; Davis R; Reue K; Tontonoz P; Beigneux AP; Fong LG; Young SG
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):230-5. PubMed ID: 22173228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
    Farese RV; Véniant MM; Cham CM; Flynn LM; Pierotti V; Loring JF; Traber M; Ruland S; Stokowski RS; Huszar D; Young SG
    Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6393-8. PubMed ID: 8692825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons.
    Beigneux AP; Davies BS; Gin P; Weinstein MM; Farber E; Qiao X; Peale F; Bunting S; Walzem RL; Wong JS; Blaner WS; Ding ZM; Melford K; Wongsiriroj N; Shu X; de Sauvage F; Ryan RO; Fong LG; Bensadoun A; Young SG
    Cell Metab; 2007 Apr; 5(4):279-91. PubMed ID: 17403372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of chylomicron remnants and beta-very low density lipoproteins to hepatic and extrahepatic lipoprotein receptors. A process independent of apolipoprotein B48.
    Hui DY; Innerarity TL; Milne RW; Marcel YL; Mahley RW
    J Biol Chem; 1984 Dec; 259(24):15060-8. PubMed ID: 6096356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women.
    Lamon-Fava S; Diffenderfer MR; Barrett PHR; Wan WY; Postfai B; Nartsupha C; Dolnikowski GG; Schaefer EJ
    Lipids; 2018 Feb; 53(2):167-175. PubMed ID: 29537647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective chylomicron synthesis as a cause of delayed particle clearance in diabetes?
    Phillips C; Madigan C; Owens D; Collins P; Tomkin GH
    Int J Exp Diabetes Res; 2002; 3(3):171-8. PubMed ID: 12458658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects.
    Franssen R; Young SG; Peelman F; Hertecant J; Sierts JA; Schimmel AW; Bensadoun A; Kastelein JJ; Fong LG; Dallinga-Thie GM; Beigneux AP
    Circ Cardiovasc Genet; 2010 Apr; 3(2):169-78. PubMed ID: 20124439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPIHBP1 and lipolysis: an update.
    Beigneux AP; Weinstein MM; Davies BS; Gin P; Bensadoun A; Fong LG; Young SG
    Curr Opin Lipidol; 2009 Jun; 20(3):211-6. PubMed ID: 19369870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.
    Beigneux AP; Miyashita K; Ploug M; Blom DJ; Ai M; Linton MF; Khovidhunkit W; Dufour R; Garg A; McMahon MA; Pullinger CR; Sandoval NP; Hu X; Allan CM; Larsson M; Machida T; Murakami M; Reue K; Tontonoz P; Goldberg IJ; Moulin P; Charrière S; Fong LG; Nakajima K; Young SG
    N Engl J Med; 2017 Apr; 376(17):1647-1658. PubMed ID: 28402248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPIHBP1 and Plasma Triglyceride Metabolism.
    Fong LG; Young SG; Beigneux AP; Bensadoun A; Oberer M; Jiang H; Ploug M
    Trends Endocrinol Metab; 2016 Jul; 27(7):455-469. PubMed ID: 27185325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slower catabolism of apo B48 than of apo B100 in triglyceride-rich lipoproteins during heparin infusions in type 5 hyperlipoproteinemic subjects.
    Nestel P; Billington T
    Metabolism; 1987 Feb; 36(2):172-5. PubMed ID: 3807788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.
    Castro Cabezas M; Erkelens DW; Kock LA; De Bruin TW
    Eur J Clin Invest; 1994 Oct; 24(10):669-78. PubMed ID: 7851467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.